Personal information | |||
---|---|---|---|
Date of birth | 5 July 1963 | ||
Height | 1.87 m (6 ft 2 in) | ||
Position(s) | midfielder | ||
Senior career* | |||
Years | Team | Apps | (Gls) |
1987–1999 | Lommelse S.K. | ||
*Club domestic league appearances and goals |
Gert Cannaerts (born 5 July 1963) is a retired Belgian football midfielder. [1]
Gert Verheyen is a Belgian retired footballer and manager, who was last in charge of Oostende.
The following are the football (soccer) events of the year 1943 throughout the world.
Gert Kruys is a Dutch football manager and former player. He is currently the manager of IJsselmeervogels.
Gert Aandewiel is a Dutch football manager and former football player.
Gert Kams is a retired Estonian professional footballer who played as a right back. From 2019 he works as a sporting director for Paide Linnameeskond.
Gert Heidler is a former German footballer and football manager.
Gert Olesk is an Estonian football coach and former professional player. He played the position of defender.
Gert Engels is a German football manager and former player. He most recently coached Nadeshiko League club INAC Kobe Leonessa.
Gert is a mainly masculine given name with some female bearers.
Gert "Charly" Dörfel is a German former professional footballer who played as a striker or winger.
Aalbeke is a village in the Belgian province of West Flanders and since 1977 a part of Kortrijk. Aalbeke has 8511 as a postal code and covers an area of 717 ha. The district had 2,953 inhabitants on December 31, 2007.
Gert Brauer was a German footballer.
APP-FUBINACA is an indazole-based synthetic cannabinoid that has been sold online as a designer drug. Pharmacological testing showed APP-FUBINACA to have only moderate affinity for the CB1 receptor, with a Ki of 708 nM, while its EC50 was not tested. It contains a phenylalanine amino acid residue in its structure.
Diphenpipenol is an opioid analgesic drug invented in the 1970s by Dainippon Pharmaceutical Co. It is chemically a 1-substituted-4-(1,2-diphenylethyl)piperazine derivative related to compounds such as MT-45 and AD-1211, but diphenpipenol is the most potent compound in the series, with the more active (S) enantiomer being around 105 times the potency of morphine in animal studies. This makes it a similar strength to fentanyl and its analogues, and consequently diphenpipenol can be expected to pose a significant risk of producing life-threatening respiratory depression, as well as other typical opioid side effects such as sedation, itching, nausea and vomiting.
MDMB-4en-PINACA is an indazole-based synthetic cannabinoid that has been sold online as a designer drug. MDMB-4en-PINACA was first identified in Europe in 2017. In 2021, MDMB-4en-PINACA was the most common synthetic cannabinoid identified by the Drug Enforcement Administration in the United States. MDMB-4en-PINACA differs from 5F-MDMB-PINACA due to replacement of 5-fluoropentyl with a pent-4-ene moiety (4-en).
5F-CUMYL-PEGACLONE (5F-SGT-151, SGT-269) is a gamma-carboline based synthetic cannabinoid that has been sold as a designer drug, first being identified in Germany in 2017. It acts as a potent full agonist of the CB1 receptor. It appears to be more toxic than related compounds such as CUMYL-PEGACLONE, and has been linked to numerous serious adverse reactions, some fatal.
CUMYL-CBMICA (SGT-280) is an indole-3-carboxamide based synthetic cannabinoid receptor agonist which has been sold as a designer drug, first being identified in Germany in August 2019. Since the structure fell outside the German drug analogue law provisions at the time, an amendment was made to the law to expand the relevant definition, which came into effect in April 2020. It has been shown to act as a CB1 receptor agonist with an EC50 of 62.9nM.
ADB-BINACA (also known as ADMB-BZINACA using EMCDDA naming standards) is a cannabinoid designer drug that has been found as an ingredient in some synthetic cannabis products. It was originally developed by Pfizer as a potential analgesic, and is a potent agonist of the CB1 receptor with a binding affinity (Ki) of 0.33 nM and an EC50 of 14.7 nM.
ADB-4en-PINACA is a cannabinoid designer drug that has been found as an ingredient in some synthetic cannabis products, first appearing in early 2021. It is a reasonably potent cannabinoid agonist in vitro but has not been so widely sold as related compounds such as ADB-PINACA and MDMB-4en-PINACA.